Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals has signed an agreement to acquire certain rights relating to a patented orally disintegrating tablet (ODT) drug delivery technology that can be used to advance the market acceptance of its Zertane product for premature ejaculation.
Subscribe to our email newsletter
The deal provides additional intellectual property to protect Zertane ODT formulation, that allows for rapid oral absorption, without the need for liquids.
The acquisition of the drug delivery technology will enhance and allow Ampio’s filing of marketing authorisation applications for product regulatory approvals of Zertane globally.
Ampio Pharmaceuticals CEO Don Wingerter said the acquisition of the drug delivery technology will help in the manufacturing and commercialisation plan for Zertane.
”We are committed to complete the development of a combination product of Zertane with a PDE5 inhibitor to simultaneously treat both premature ejaculation and erectile dysfunction,” Wingerter added.
The close of the transaction is subject to customary conditions, including a certain third party consent and completion of a technology and materials transfer plan.